The European Medicines Agency (EMA) has recommended that a new oral agent, Welireg (belzutifan), be granted conditional ...

Merck & Co. said a key European regulatory committee has recommended conditional approval of its Welireg oral cancer drug in a pair of indications.

Consistent with the principles of the 3Rs in Animal Experimentation (Hubrecht and Carter, Animals (Basel) 2019, 9, 754) ...

The tyrosine kinase inhibitors market is expected to grow significantly over the next decade, driven by continued innovation, rising cancer awareness, and increased adoption of targeted therapies.